Biosimilars have the potential to lower costs. But due to middlemen like pharmacy benefit managers (PBMs), those savings don’t always trickle down to patients at the pharmacy counter. How can we fix this system? Julie Reed, executive director of the...
Biosimilars have the potential to lower costs. But due to middlemen like pharmacy benefit managers (PBMs), those savings don’t always trickle down to patients at the pharmacy counter. How can we fix this system?
Julie Reed, executive director of the Biosimilars Forum, joins the podcast to explain what biosimilars are, why uptake has been slow, and what can be done to improve patient access and lower costs.
We also hear from Lauren Kopsick, who shares her experience navigating burdensome step therapy requirements for her son’s care.
Hosts:
Terry Wilcox, Executive Director, Patients Rising
Dr. Robert Goldberg, “Dr. Bob,” Co-Founder and Vice President of the Center for Medicine in the Public Interest
Kate Pecora, Field Correspondent
Guests:
Julie Reed, Executive Director, Biosimilars Forum
Lauren Kopsick, Founder, Parent it Forward
Becca Vacha, Patient Correspondent
Links:
Patients Rising Now Announces Masterclass Graduates
Learning Module: The Role Biologics & Biosimilars Can Play in Healthcare
Lend Your Voice to Support the Safe Step Act Here
Need help?
The successful patient is one who can get what they need when they need it. We all know insurance slows us down, so why not take matters into your own hands? Our Navigator is an online tool that allows you to search a massive network of health-related resources using your zip code so you get local results. Get proactive and become a more successful patient right now at PatientsRisingConcierge.org
Have a question or comment about the show, or want to suggest a show topic or share your story as a patient correspondent?
Drop us a line: podcast@patientsrising.org
The views and opinions expressed herein are those of the guest(s)/ author(s) and do not reflect the official policy or position of Patients Rising.